Skip to main content

Hematopoietic Stem Cell Transplantation in Late-onset X-linked Chronic Granulomatous Disease in a Female Carrier

A Correction to this article was published on 11 August 2022

This article has been updated

This is a preview of subscription content, access via your institution.

Fig. 1

Data Availability

Not applicable.

Code Availability

Not applicable.

Change history

Abbreviations

AUC:

Area Under the Curve

CGD:

Chronic Granulomatous Disease

DHR:

Dihydrorhodamine assay

GVHD:

Graft Versus Host Disease

HSCT:

Hematopoietic Stem Cell Transplantation

IFNγ:

Interferon-gamma

NADPH:

Nicotinamide Adenine Dinucleotide Phosphate

NIH:

National Institutes of Health

PBSC:

Peripheral Blood Stem Cells

PMA:

Phorbol 12-Myristate 13-Acetate

References

  1. Marciano BE, Zerbe CS, Falcone EL, et al. X-linked carriers of chronic granulomatous disease: illness, lyonization, and stability. J Allergy Clin Immunol. 2018;141(1):365–71.

    CAS  Article  Google Scholar 

  2. Ezekowitz RAB, Orkin SH, Newburger PE. Recombinant interferon gamma augments phagocyte superoxide production and X-chronic granulomatous disease gene expression in X-linked variant chronic granulomatous disease. J Clin Invest. 1987;80(4):1009–16.

    CAS  Article  Google Scholar 

  3. Güngör T, Teira P, Slatter M, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet. 2014;383(9915):436–48.

    Article  Google Scholar 

  4. Parta M, Kelly C, Kwatemaa N, et al. Allogeneic reduced intensity hematopoietic stem cell transplantation for chronic granulomatous disease: a single-center prospective Trial. J Clin Immun. 2017;37:548–58.

    CAS  Article  Google Scholar 

  5. Parta M, Hilligoss D, Kelly C, et al. Failure to prevent severe graft-versus-host disease in haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in chronic granulomatous disease. J Clin Immunol. 2020;40(4):619–24.

    CAS  Article  Google Scholar 

Download references

CGD consortium members

Francesco Salton6, Barbara Ruaro6, Chiara Torregiani6, Paola Confalonieri6, Samuele Naviglio5, Erica Valencic5, Marco Gabrielli2, Mark Parta3, Corin Kelly4, Luigi D. Notarangelo4, Harry L. Malech4

Funding

This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E and Contract No. 75N910D00024, Task Order No. 75N91019F00131. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Author information

Authors and Affiliations

Authors

Consortia

Contributions

All authors contributed to the study conception and design. The first draft of the manuscript was written by MT and EMK. FS, BR, CT, MG, PC, CK, MP, EMK, AT, HLM, and MC cared for the patient. Material preparation, clinical data collection, and analysis were performed by EV, SN, MP, and AT. LDN, AT, HLM and MC reviewed and improved the final draft. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Matteo Trevisan.

Ethics declarations

Consent to Participate

The patient gave informed consent to participate in this research.

Consent for Publication

The patient’s consent to publish was obtained. A signed informed consent was obtained from the patient to publish her data in this journal article. This form is available for review upon request.

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Trevisan, M., Kang, E.M., CGD Consortium. et al. Hematopoietic Stem Cell Transplantation in Late-onset X-linked Chronic Granulomatous Disease in a Female Carrier. J Clin Immunol (2022). https://doi.org/10.1007/s10875-022-01310-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s10875-022-01310-9